Researchers are planning a clinical trial after four metastatic FGFR2 fusion-positive pancreatic cancer patients responded to ...
The agency is considering whether to limit the indications of Keytruda, Opdivo, and Tevimbra to PD-L1-positive patients amid testing uncertainties.
The agency converted a prior accelerated approval to a traditional approval based on results from the LIBRETTO-531 trial.
Researchers hope DeepGEM can expedite targeted treatment for lung cancer patients who can't access standard genomic testing.
The Florida-based provider will work with AI software company AiraMed to analyze and measure patients' brain volume from MRIs.
NEW YORK – 858 Therapeutics on Thursday said it raised $50 million in a Series B financing round to advance its pipeline of small molecule therapeutics, including the poly (ADP) ribose glycohydrolase ...
In a report, a working group cautioned that the program must lessen its reliance on congressional appropriations or risk ...
The third-generation EGFR inhibitor will now be an option for patients whose tumors are not metastatic but can't be removed with surgery.
Experts noted, however, there is insufficient evidence to determine which commercially available KRAS G12C inhibitor is the ...
NEW YORK – ReCode Therapeutics on Thursday said it has treated the first cystic fibrosis patient with its inhaled messenger RNA (mRNA) therapy within a Phase Ib trial. Investigators will assess the ...